newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

  • Praxis Precision Medicines announced an expert call on Deep Dive into Ulixacaltamide Data scheduled for November 24, 2025, at 1:00pm EST.
  • The call will feature HCWainwright analyst Doug Tsao, statistician Prof. Chuck McCullogh from UCSF, & Praxis CEO Marcio Souza.
  • Registration for the event is available via a provided link.
  • Praxis is a clinical-stage biopharmaceutical company focused on CNS disorders characterized by neuronal excitation-inhibition imbalance.
  • The company utilizes its proprietary Cerebrum™ small molecule platform & Solidus™ antisense oligonucleotide (ASO) platform to develop therapies.
  • Praxis currently holds a diversified CNS portfolio with four clinical-stage product candidates across epilepsy & movement disorders.